About: Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids
Creator	Wang, Hui Wang, Pengfei Xu, Dong Wang, Xing Schwartz, Robert Nguyen, Duc Han, Yuling Ho, David Zhang, Tuo Zhao, Zeping Tenoever, Benjamin Bram, Yaron Cantley, Lewis Chen, Huanhuan Chen, Shuibing Cheng Pan, Fong Duan, Xiaohua Duan, Evans, Todd Houghton, Sean Huang, Yaoxing Johnson, Jared Nilsson-Payant, Benjamin Redmond, David Tang, Xuming Uhl, Skyler Xiang, Jenny Yang, Liuliu Yaron, Tomer
Source	BioRxiv; Medline
abstract	The SARS-CoV-2 virus has caused already over 3.5 million COVID-19 cases and 250,000 deaths globally. There is an urgent need to create novel models to study SARS-CoV-2 using human disease-relevant cells to understand key features of virus biology and facilitate drug screening. As primary SARS-CoV-2 infection is respiratory-based, we developed a lung organoid model using human pluripotent stem cells (hPSCs) that could be adapted for drug screens. The lung organoids, particularly aveolar type II cells, express ACE2 and are permissive to SARS-CoV-2 infection. Transcriptomic analysis following SARS-CoV-2 infection revealed a robust induction of chemokines and cytokines with little type I/III interferon signaling, similar to that observed amongst human COVID-19 pulmonary infections. We performed a high throughput screen using hPSC-derived lung organoids and identified FDA-approved drug candidates, including imatinib and mycophenolic acid, as inhibitors of SARS-CoV-2 entry. Pre- or post-treatment with these drugs at physiologically relevant levels decreased SARS-CoV-2 infection of hPSC-derived lung organoids. Together, these data demonstrate that hPSC-derived lung cells infected by SARS-CoV-2 can model human COVID-19 disease and provide a valuable resource to screen for FDA-approved drugs that might be repurposed and should be considered for COVID-19 clinical trials.
has issue date	2020-05-05(xsd:dateTime)
bibo:doi	10.1101/2020.05.05.079095
bibo:pmid	32511403
has license	biorxiv
sha1sum (hex)	aa2dfb1bad9aa849fded4324ecff9f3ba99184be
schema:url	https://doi.org/10.1101/2020.05.05.079095
resource representing a document's title	Identification of Candidate COVID-19 Therapeutics using hPSC-derived Lung Organoids
has PubMed identifier	32511403
schema:publication	bioRxiv
resource representing a document's body	covid:aa2dfb1bad9aa849fded4324ecff9f3ba99184be#body_text
is schema:about of	named entity 'biology' named entity 'ACE2' named entity 'virus' named entity 'study' named entity 'SARS-CoV-2' named entity 'infection' named entity 'drug screening' named entity 'SARS-CoV-2' named entity 'lung' named entity 'SARS-CoV-2' named entity 'Organoids' named entity 'Lung' named entity 'c-kit' named entity 'staining' named entity 'hPSC' named entity 'imatinib' named entity 'respiratory failure' named entity 'SP-B' named entity 'Histology' named entity 'IL-17' named entity 'ethanol' named entity 'SARS-CoV-2' named entity 'penicillin' named entity '0.01' named entity 'vaccine' named entity 'TMPRSS2' named entity 'organ systems' named entity 'mitochondria' named entity 'Immunostaining' named entity 'RNA-seq' named entity 'imatinib' named entity 'protein' named entity 'virus' named entity 'virus' named entity 'Vero cells' named entity 'fatty acid biosynthesis' named entity 'ACE2' named entity 'hPSC' named entity 'necropsy' named entity 'luciferase' named entity 'endoderm' named entity 'SARS-CoV-2' named entity 'receptor' named entity 'organ' named entity 'Student's t test' named entity 'fatty acid metabolism' named entity 'prochlorperazine' named entity 'hPSC' named entity 'virion' named entity 'SARS-CoV-2' named entity 'viral RNA' named entity 'coronavirus' named entity 'DMEM' named entity 'Immunostaining'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software